Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 maintenance study of TAK-390MR versus placebo in healed erosive esophagitis
2006-000419-90Phase 3Completed
- Sponsor
- TAP Pharmaceutical Products
- Start
- May 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dexlansoprazole in erosive esophagitis (EE) (3 arms), sponsored by TAP Pharmaceutical Products. Primary endpoint: Maintenance of complete healing of erosive esophagitis. Started May 2006; status: completed.
02
Drugs
dexlansoprazole
03
Conditions
erosive esophagitis (EE)
Beyond the preview
Go deeper on 2006-000419-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000419-90.